Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 2 October 2017

Vistin Pharma ASA : Sale of Opioids and CMO business completed

Vistin Pharma ASA    

Published: 10:28 CEST 02-10-2017 /GlobeNewswire /Source: Vistin Pharma ASA / : VISTIN /ISIN: NO0010734122

Vistin Pharma ASA : Sale of Opioids and CMO business completed

Oslo, Norway, 2 October 2017

Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Company has successfully completed the sale of its opioids and tablet manufacturing business (CMO) to TPI Enterprises Limited ("TPI"). Reference is made to the stock exchange announcements on 11 July and 13 July.

TPI has paid a provisional cash consideration of NOK 159.5 million, which will be adjusted for changes in inventory between the time of signing the sales and purchase agreement and the completion date. The transaction is expected to have a positive net cash effect of NOK 140 - 150 million, before any transaction costs.

Following the sale, Vistin Pharma is a pure play metformin producer, with a strong position in the global metformin market and with significant growth ambitions. Metformin is used as the 1st line treatment of diabetes 2, a disease which is expected to grow by 50% towards 2030, and affect more than 500 million people. The global market for metformin is expected to grow by four to five percent per annum and Vistin Pharma is attractively positioned to capture part of this growth.

For further information, please contact:

Kjell-Erik Nordby
+47 91 36 42 80

Gunnar Manum
+47 95 17 91 90

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Vistin Pharma ASA, P.O. Box 6735 Etterstad, Oslo 0609, Norway
If you would like to unsubscribe and stop receiving these e-mails click here.